$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Tepotinib continues to show positive results in METex14-skipped NSCLC
2026-02-01 22:25:32
Check Details
Tepotinib combined with osimertinib may provide a chemotherapy-free option for patients with non-small cell lung cancer after first-line osimertinib treatment
2026-02-01 22:25:32
Check Details
Tepotinib/osimertinib combination induces ORR benefit in EGFR mutated non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Tepotinib and gefitinib show long OS in MET-amplified EGFR+ non-small cell lung cancer
2026-02-01 22:25:32
Check Details
Tepotinib demonstrates durable benefits of high-level methionine MET amplification
2026-02-01 22:25:32
Check Details
Tepotinib shows strong response in lung cancer subgroups during long-term follow-up
2026-02-01 22:25:32
Check Details
Tepotinib launch date in China
2026-02-01 22:25:32
Check Details
Tepotinib PFS
2026-02-01 22:25:32
Check Details
How much does Tepotinib cost in 2023
2026-02-01 22:25:32
Check Details
Tepotinib is a first-generation targeted drug
2026-02-01 22:25:32
Check Details
Indications for Tepotinib
2026-02-01 22:25:32
Check Details
How much does one bottle of Tepotinib cost?
2026-02-01 22:25:32
Check Details
1
2
...
368
369
370
371
372
373
374
...
10236
10237
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Pemigatinib for FGFR2-Rearranged Cholangiocarcinoma: Eligibility, Response Limits, Hyperphosphatemia and Ocular Monitoring
2
Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs
3
Bosentan Key Prescribing Points: Indication, Dosage, Risks, and Monitoring
4
Ambrisentan and IgA Nephropathy: Does It Reduce Proteinuria and Is It Safe?
5
Stiripentol for Dravet Syndrome With Clobazam: Weight-Based Dosing, Food Administration, Somnolence and Blood Count Monitoring
6
In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances
7
Acalabrutinib BTK Covalent Inhibition: CLL/SLL Signaling Blockade, Non-Selective Effects, and Progression Monitoring
8
Bosutinib for Ph+ CML: Eligible Populations, Food-Dependent Dosing, Diarrhea and Hepatotoxicity Monitoring
9
Hovilpri (Pritelivir) Oral Anti-HSV: Immunocompromised Adults With Acyclovir-Refractory Mucocutaneous Lesions, 63% Healing at 28 Days
10
Venetoclax BCL-2 Inhibitor: CLL/SLL and AML Ramp-Up, Tumor Lysis Prevention, and Selected Overseas Combination Updates
11
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
12
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT